Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen2010 · 206 citations
2. 2Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity2010 · 2,072 citations
3. 3FDA Approval: Blinatumomab2015 · 364 citations
4. 4A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens2011 · 103 citations
5. 5RECRUIT-TandAbs ^® : Harnessing the Immune System to Kill Cancer Cells2012 · 35 citations